---
document_datetime: 2025-07-18 15:56:50
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/osenvelt-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: osenvelt-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.5451304
conversion_datetime: 2025-12-29 23:04:13.215846
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Osenvelt

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                     | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                          |
|----------------------|-------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|--------------------------------------------------|
| Variation type IB /  | C.I.2 Change(s) in the Summary of Product | 18/07/2025                          |                                             | SmPC,                            | To update Section 4.8 of the SmPC to include the |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000284948   | Labelling and PL   | frequences of osteonecrosis of the jaw, atypical fractures of the femur and new primary malignancy in patients with giant cell tumour of bone (GCTB) based on the results from study 20140114. The change follows assessment of the same change for the reference product, Xgeva.   |
|---------------------|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

| Article 61(3) / EMA/N/0000266442      | - Notification acc. Article 61(3) - Update of the package leaflet with revised contact details of local representatives and removal of grey-shading of manufacturers in section '6. Contents of the pack and other information'.                                                                                                                                                                                            | 15/05/2025   | PL          |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------------|
| Variation type IB / EMA/VR/0000263750 | This was an application for a group of variations. B.II.f.1.b Extension of the shelf life of the finished product - B.II.f.1.b.5 Extension of the shelf-life of a biological/ immunological medicinal product in accordance with an approved stability protocol - Accepted B.II.f.1 Change in the shelf-life or storage conditions of the finished product - B.II.f.1.e Change to an approved stability protocol - Accepted | 25/04/2025   | SmPC and PL |